Happy Friday!
A new study came out in Nature Communications last week, and it contained some pretty exciting info about GLP-1s.
The title is “Semaglutide Slows Epigenetic Aging”.
It’s a little more nuanced than that, and today I want to walk you through the findings, as I think they are highly relevant to the future of longevity medicine.
Have you checked out my AI tool yet? Join over 12k monthly active users who are using it to get their questions answered directly from my videos and content by clicking here: https://chat.hunterwilliamshealth.com/
The Study
In the study, researchers ran a clinical trial on once-weekly semaglutide.
Half the people got the drug. Half got a placebo shot of saline. It was a blind study, meaning nobody knew who got what, not even the doctors.
45 people were given semaglutide. 39 were given a placebo. The duration was 32 weeks.
The participants all had HIV, and all carried excess fat around their organs. That's a group that ages faster than normal, making it a good place to look for an aging signal.
At the start and at the end, the researchers drew blood and froze it. Later, they went back and measured something called DNA methylation.
What is DNA methylation?
Essentially, your DNA is the instruction manual for your body.
Over time, your cells stick tiny chemical tags onto certain pages of that manual. Some tags turn a page off. Some turn it back on.
The tags accumulate in patterns as you age. You can read the pattern to estimate how old someone's body actually is biologically, separate from their birthday (chronological age).
That's a methylation clock.
There are a lot of them.
But they don't all measure the same thing.
The Aging Clocks
The researchers ran 17 different clocks on the same blood samples.
Picture your body as a car.
Some of these clocks look at the dashboard. They were built by studying thousands of people's blood tests. Things like inflammation, blood sugar, and cholesterol.
The scientists found which chemical tags on the DNA tend to show up when someone's bloodwork looks bad. Then they turned that into an age number.
So a dashboard clock is really asking one simple question. How does this person's blood look today?
Other clocks were built to look under the hood. Three of them are called AdaptAge, CausAge, and DamAge.
The scientists who made them wanted to find real, permanent wear on the parts, not just what the dashboard says this morning.
One more clock check to see how the car actually drives. Grip strength. Walking speed. Memory and thinking. Can this body still do what a younger body does?
Well, here’s what happened in the study.
Every dashboard (bloodwork) clock moved. The people on semaglutide aged more slowly on all of them.
Every under-the-hood clock stayed exactly where it was.
The one that checks how the car drives also stayed put.
Semaglutide is very good at improving bloodwork. W have known this for years.
So when a clock built out of bloodwork says these people got younger, part of what you are seeing is that clock doing its job. The blood markers looked better.
The clocks built to detect deep wear in the parts showed no improvement and no worsening.
In summary, although the bloodwork improved, the tangible markers stayed the same, which in my view is actually a win for people with HIV induced lipodystrophy.
The same thing showed up when they looked at organs one by one.
Heart, liver, kidney, brain, and inflammation all improved.
Lungs, immune system, hormones, and muscles did not move at all.
My Interpretation
This study is telling us something about the aging accelerator.
Extra fat around your organs and low-grade inflammation in your blood push the gas pedal of aging down.
That's what an accelerator does. It makes everything run faster and wear out sooner.
These participants were carrying a heavy foot on that pedal. Semaglutide lifted it a little.
And when it did, the gauges read better.
The fat and the inflammation are the accelerator. Anything that removes them should show up the same way.
Future Prospects
If the accelerator is what matters, then the size of the effect should track with how much of it you take away.
The semaglutide dose used here was 1mg.
It's the weakest tool we have now.
Tirzepatide beats it on visceral fat reduction. Retatrutide beats tirzepatide, and it's still moving through trials.
If this thesis is right, those drugs should move these same clocks even further than semaglutide.
But for now, we can step back and appreciate what just happened.
This was a randomized trial in living human beings with a placebo group, in which a drug measurably altered markers of biological aging.
Nothing like that has existed before for this class of medication.
The Caveat
In this study, the muscle clock didn’t move.
At this modest dose, with modest weight loss, that's fine. Nothing gained, nothing lost.
But push to heavier weight loss with a stronger drug, and you have a problem.
You could improve every inflammation marker in the panel while quietly losing muscle.
You improve the gauges, but the engine gets worse.
Muscle is one of the strongest predictors of how well you age and how long you stay independent.
Drop a quarter of your bodyweight and let a third of it come from muscle, and you have traded one aging problem for another.
Which means lifting weights and eating enough protein are not optional add-ons while you're on one of these drugs. They ARE the treatment. The drug is the assistant.
Future Implications
In this study, the semaglutide group didn't reverse age and get younger, but they did hold steady.
The placebo group aged about two years in eight months.
The control group continued to worsen, while the semaglutide-treated group had their damage delayed.
I think that’s the key word here. Delayed.
These participants had a foot on the accelerator of aging, and semaglutide delayed that aging by taking pressure off the accelerator.
When it comes to applying intelligent use of GLP-1s, we want to catch the accelerator while it's still just an accelerator and before the engine wears out.
Final Thoughts
For a hundred years, we treated aging similar to the weather.
Something that happens to you. You manage the symptoms, one disease at a time, until you run out of road.
This study is small, has real limitations, and the authors say so plainly.
But it is a randomized human trial in which a licensed, widely available drug altered the pace of biological aging.
For now, we do not know who benefits most, or how long the effect holds, or what happens over decades.
Those questions take another ten years of work.
Still, the ground shifted last week.
For most of medicine's history, the rate of aging was something you inherited from your parents and managed as best you could.
Now it looks like we have the tools to potentially delay aging directly, if used intelligently.
Have a fantastic weekend!
Best,
Hunter Williams
Source
Corley, M.J., Dwaraka, V.B., Pang, A.P. et al. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nat Commun (2026). https://doi.org/10.1038/s41467-026-72861-3